直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 118639
タイトル別表記
A multicenter survey for submacular hemorrhage
著者
Kimura, Takeshi Hyogo College of Medicine
Araki, Takashi Hyogo College of Medicine
Yasukawa, Tsutomu Nagoya City University
Kato, Aki Nagoya City University
Kuwayama, Soichiro Nagoya City University
木下, 貴正 Sapporo City General Hospital
Okamoto, Fumiki University of Tsukuba
Murakami, Tomoya University of Tsukuba
Sakamoto, Taiji Kagoshima University
Terasaki, Hiroto Kagoshima University
Kusuhara, Sentaro Kobe University
Miki, Akiko Kobe University
Takamura, Yoshihiro Fukui University
Kondo, Mineo Mie University
Matsubara, Hisashi Mie University
Ueda, Tetsuo Nara Medical University
Tsujinaka, Hiroki Nara Medical University
Gomi, Fumi Hyogo College of Medicine
資料タイプ
学術雑誌論文
抄録
Purpose
To evaluate the clinical characteristics, treatment trends, and visual prognosis of submacular hemorrhage (SMH) secondary to neovascular age-related macular degeneration (nAMD) and retinal arterial macroaneurysm (RAM).
Methods
This retrospective study enrolled 187 Japanese patients with SMH at 10 institutions from 2015 to 2018. Medical records including SMH etiology, best-corrected visual acuity (BCVA), fundus photographs, optical coherence tomography images, and selected treatments were analyzed.
Results
Major causes of SMH were typical nAMD (tnAMD) (18%), polypoidal choroidal vasculopathy (PCV) (50%) and RAM (29%). Age, male/female ratio, baseline BCVA, central retinal thickness, and involved retinal layers were significantly different between etiologies (all P<0.0001). Treatment with anti-vascular endothelial growth factor drugs with and without intravitreal gas injection was chosen for half of eyes in the tnAMD and PCV groups, whereas vitrectomy was performed in 83.7% of eyes with RAM. The final BCVA improved significantly from baseline in the PCV and RAM groups (P = 0.0009, P<0.0001) and final BCVA was significantly better in the PCV group at a level similar to the other groups (P = 0.0007, P = 0.0008). BCVA improvement from baseline was significantly greater in the RAM group compared with the tnAMD (P = 0.0152) and PCV (P = 0.017) groups. Multivariate analysis revealed better final BCVA was significantly associated with younger age (P = 0.0054), better baseline BCVA (P = 0.0021), RAM subtype (P = 0.0446), and no tnAMD (P = 0.001).
Conclusions
The characteristics of, and treatment strategy for, SMH were different between the underlying diseases. Anti-vascular endothelial growth factor treatment with or without expansile gas was mainly chosen for SMH in tnAMD and PCV, whereas vitrectomy with gas was the most common treatment for RAM, and the higher rate for vitrectomy might result in the greater BCVA improvement in the RAM group than in the other groups. Final BCVA was better in PCV, RAM, and tnAMD, in that order, because patients with PCV were younger and had better baseline BCVA.
掲載誌名
PLOS ONE
ISSN
19326203
出版者
PLOS
17
9
開始ページ
e0274508
発行日
2022-09-29
権利情報
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
病院
医学系